Rimegepant

Indications

Rimegepant is used for: Migraine Treatment

Adult Dose

Migraine Treatment Indicated for acute treatment of migraine with or without aura 75 mg PO Not to exceed 75 mg per 24-hr period Safety of treatment >15 migraines/30 days has not been established Hepatic impairment Mild or moderate (Child-Pugh A or B): No dosage adjustment required Severe: Avoid

Child Dose

Renal Dose

Renal impairment Mild, moderate, or severe (CrCl ?15 mL/min): No dosage adjustment required End-stage renal disease (CrCl <15 mL/min): Avoid; not studied

Administration

Use dry hands when opening blister pack Peel back foil covering of 1 blister and gently remove the orally disintegrating tablet (ODT); do not push the ODT through the foil As soon as the blister is opened, remove ODT and place on the tongue; alternatively, the ODT may be placed under the tongue ODT disintegrates in saliva so that it can be swallowed without additional liquid Take the ODT immediately after opening the blister pack; do not store ODT outside the blister pack for future use

Contra Indications

History of hypersensitivity to rimegepant; delayed serious hypersensitivity reported

Precautions

Hypersensitivity Hypersensitivity reactions, including dyspnea and rash, reported Hypersensitivity reactions can occur days after administration, and delayed serious hypersensitivity has occurred If a hypersensitivity reaction occurs, discontinue rimegepant and initiate appropriate therapy

Pregnancy-Lactation

Pregnancy Data are not available regarding the developmental risk associated with use in pregnant women Clinical considerations Data suggest that women with migraine may be at increased risk of preeclampsia and gestational hypertension during pregnancy Animal studies Oral administration during organogenesis resulted in adverse effects on development in rats (decreased fetal body weight and increased incidence of fetal variations) at exposures greater than those used clinically and which were associated with maternal toxicity Lactation Data are not available on the presence in human milk, effects on breastfed infants, or effects on milk production There are no animal data on the excretion of rimegepant in milk

Interactions

Side Effects

Side effects of Rimegepant : 1-10% Nausea (2%) <1% Hypersensitivity, including dyspnea and severe rash

Mode of Action

Calcitonin gene-related peptide (CGRP) receptor antagonist; binds to CGRP receptor, which is thought to be causally involved in migraine pathophysiology